Efruxifermin, an FGF21 analog (phase IIa), was evaluated with once-weekly dosing, including 80 patients with biopsy-proven NASH (NCT03976401) who were given efruxifermin at three different dose levels (28 mg, 50 mg, and 70 mg) for 16 weeks and showed a significant reduction in hepatic fat in patients with NASH and F1–F3 fibrosis. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.